摘要
目的探讨瑞舒伐他汀对高血压合并高脂血症患者超敏C-反应蛋白的影响。方法72例高血压病合并高血脂患者,在常规降压治疗基础上加服瑞舒伐他汀10 mg,睡前服用,1次/天,80例单纯高脂血症患者,睡前服用瑞舒伐他汀10 mg,1次/天。另选取年龄性别等相匹配60例正常体检者为对照组。治疗时间12周。检测治疗前后3组研究对象血压、血脂、超敏C反应蛋白(hsCRP)等因素的变化。结果治疗前高血压病合并高脂血症组的血压和血脂明显高于对照组,经降压和降脂治疗后血压与血脂显著下降(P<0.05)。高血压病合并高血脂组超敏C-反应蛋白的水平明显高于正常对照组(P<0.01),瑞舒伐他汀治疗后超敏C-反应蛋白水平显著下降(P<0.01)。结论瑞舒伐他汀可明显降低高血压病合并高脂血症患者超敏C-反应蛋白水平,从而可能改善高血压病合并高脂血症患者的炎症状态,减缓动脉粥样硬化的形成。
Objective To study the effect of rosuvastatin on high sensitive C-reactive protein （hsCRP） in patients with essential hypertension and hyperlipidemia. Methods 72 hypertensive patients with hyperlipidemia received conventional antihypertensive therapy and the treatment of rosuvastatin 10 mg（QN） . 80 patients with hyperlipidemia received rosuvastatin 10 mg （QN） and 60 normal subjects were served as control group. The changes of blood pressurre, lipids and hsCRP were measured before and after 12 weeks treatment. Results The level of blood pressure and lipid in rosuvastatin groups were significantly higher than that in control group before treatment （ P 〈 0. 05 ）, blood pressure and lipid were significantly decreased after treatment （ P 〈 0. 05 ） . Before treatment, the level of hsCRP in hypertensive patients with hyperlipidemia group were higher than control group （P 〈0. 01 ） . Conclusion Rosuvastatin could obviously decrease the level of hsCRP in patients with essential hypertension and hyperlipidemia, therefore may improve the inflammation and inhibit atherosclerosis.
出处
《广州医药》
2009年第1期30-32,共3页
Guangzhou Medical Journal
关键词
瑞舒伐他汀
高血压病
高脂血症
超敏C-反应蛋白
Rosuvastatin
Essential Hypertension
Hyperlipidemia
Hi-sensitive C-reactive protein （hsCRP）
